Peripheral nervous system

Newron Presents Six-Month Interim Data From the First 100 Patients Randomized in Study 014/015 at the 31st European Congress of Psychiatry

Retrieved on: 
Tuesday, March 28, 2023
Research, Mental Health, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, PANSS, Schizophrenia, TRS, XETRA, Positive, Clinical Global Impression, CNS, Clozapine, Medication, Congress, Incidence, Insomnia, Patient, European, NCE, Fever, Peripheral nervous system, Pharmaceutical industry, Risk management, Silviculture, Psychiatry

The first poster presented full results from the cohort of the first 100 patients completing six months/endpoint of treatment with evenamide in study 014/015.

Key Points: 
  • The first poster presented full results from the cohort of the first 100 patients completing six months/endpoint of treatment with evenamide in study 014/015.
  • Study 014/015 is an international, randomized, open label, rater-blinded study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS) not responding to their current antipsychotic medication.
  • 97% of patients completed six weeks of treatment, and more than 90% of the completers chose to continue with evenamide treatment into the long-term extension study (study 015).
  • The second poster detailed the characterization of “Responder” in TRS patients based on data from this study.

Feinstein Institutes researchers use novel imaging technology to study how the brain and body communicate

Retrieved on: 
Tuesday, March 21, 2023
Oncology, Mental Health, Health, Hospitals, Research, Science, Inflammation, Infection, Neuron, Medicine, Diabetes, Inflammatory Bowel Diseases, Vagus nerve, Arthritis, Respiration, Neural engineering, Feinstein Institutes for Medical Research, Cancer, Skull, Brain, Multimedia, Attention, Biomedical engineering, Doctor of Philosophy, Interface (computing), Sensation, PNS, Bangladesh Technical Education Board, Paralysis, Crohn's disease, Neuroscience, Journal, Nervous system, Mouse, Heart rate, Pulmonary hypertension, Credit, Molecular medicine, NIH, Medical research, Rheumatoid arthritis, Disease, Peripheral nervous system, Medical imaging, Medical device, MD

By using calcium imaging technology to monitor neural activity from a cluster of neurons near the base of the skull, scientists hope to discover new clues about how the body communicates with the brain.

Key Points: 
  • By using calcium imaging technology to monitor neural activity from a cluster of neurons near the base of the skull, scientists hope to discover new clues about how the body communicates with the brain.
  • The researchers used imaging of the intact jugular-nodose ganglion – which contains the sensory neurons of the vagus nerve – to directly record neural activity in mice with genetically-encoded calcium indicators.
  • In this new study, Feinstein Institutes’ bioelectronic medicine researchers look at how sensory neurons encode and transmit these important physiological signals in the form of neural activity.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Newron Reports Compelling Topline Results From All Patients in Study 014, Its Phase II Clinical Trial Evaluating Evenamide as Add-on Therapy for Treatment-resistant Schizophrenia

Retrieved on: 
Monday, March 20, 2023
Research, Mental Health, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Medication, LOF, PANSS, TRS, XETRA, Clozapine, Safety, Patient, CNS, Peripheral nervous system, Pharmaceutical industry

While the primary objective of the study was safety and tolerability of the drug, efficacy over baseline was also assessed.

Key Points: 
  • While the primary objective of the study was safety and tolerability of the drug, efficacy over baseline was also assessed.
  • Interim results from the first 100 patients at six weeks were previously reported in June 2022.
  • Notably, of the 161 patients who were randomized, 153 (95%) completed the six-week treatment period and 144 (94% of the completers) entered the extension study (Study 015).
  • Overall, the results from the complete study population are fully consistent with the findings from the first 100 patients at this timepoint.

EQS-News: Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia

Retrieved on: 
Monday, March 20, 2023
PANSS, CET, TRS, XETRA, Phase II, CNS, Clozapine, LOF, Patient, Safety, Peripheral nervous system, Pharmaceutical industry, Newron Cup

Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia

Key Points: 
  • Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
    The issuer is solely responsible for the content of this announcement.
  • Interim results from the first 100 patients at six weeks were previously reported in June 2022.
  • Notably, of the 161 patients who were randomized, 153 (95%) completed the six-week treatment period and 144 (94% of the completers) entered the extension study (Study 015).
  • Overall, the results from the complete study population are fully consistent with the findings from the first 100 patients at this timepoint.

EQS-News: Newron to present at the 31st European Congress of Psychiatry  

Retrieved on: 
Friday, March 17, 2023
CET, Psychosis, Schizophrenia, TRS, Palais, XETRA, CNS, Clozapine, Congress, Patient, European, Peripheral nervous system, Pharmaceutical industry, Psychiatry

Encouraging top-line, six-month results from this cohort of patients were announced in January 2023, and top-line one-year results were announced in February 2023.

Key Points: 
  • Encouraging top-line, six-month results from this cohort of patients were announced in January 2023, and top-line one-year results were announced in February 2023.
  • The second poster will detail the characterization of “Responder” in TRS patients based on data from this study.
  • Both posters will be presented during the “Schizophrenia and other psychotic disorders 10” session at 12:30pm CET on 28 March 2023 at e-poster area station 12.
  • Full poster titles are below:
    Poster 1: “Evenamide, as an add-on to antipsychotics, benefits patients with treatment resistant schizophrenia: 6-month interim results from the first 100 patients in an ongoing international randomized study”;

Newron to present at the 31st European Congress of Psychiatry

Retrieved on: 
Friday, March 17, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Other Health, CET, Psychosis, Schizophrenia, TRS, Palais, XETRA, CNS, Clozapine, Medication, Congress, Patient, European, Peripheral nervous system, Pharmaceutical industry, Psychiatry

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announced that it will present two e-posters at the 31st European Congress of Psychiatry, taking place on 25-28 March 2023, at the Palais des Congrès of Paris - Place de la Porte Mailot in Paris, France.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), announced that it will present two e-posters at the 31st European Congress of Psychiatry, taking place on 25-28 March 2023, at the Palais des Congrès of Paris - Place de la Porte Mailot in Paris, France.
  • Encouraging top-line, six-month results from this cohort of patients were announced in January 2023, and top-line one-year results were announced in February 2023.
  • The second poster will detail the characterization of “Responder” in TRS patients based on data from this study.
  • Both posters will be presented during the “Schizophrenia and other psychotic disorders 10” session at 12:30pm CET on 28 March 2023 at e-poster area station 12.

EQS-News: Newron announces 2022 financial results and provides outlook for 2023

Retrieved on: 
Thursday, March 16, 2023
Sympathetic nervous system, Annual report, Sale, PD, Sustainable Development Goals, Peripheral nervous system, Clozapine, Trial of the century, Levodopa-induced dyskinesia, Partnership, Orange Book, XETRA, Abbreviated New Drug Application, Paragraph, Environment, Schizophrenia, Phase, Clinical Global Impression, Patient, UN, Positive and Negative Syndrome Scale, Tablet, Psychosis, FDA, Sustainability, TRS, Social, US Foods, EUR, Sustainable development, ESG, Safety, CET, Positive, Annual, AGM, Food, Social Security Government Pension Offset, PANSS, Intellectual property, R, Pharmaceutical industry, Nursing, Cryptocurrency, Newron Cup

Milan, Italy, March 14, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2022, and provided an outlook for 2023.

Key Points: 
  • Milan, Italy, March 14, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2022, and provided an outlook for 2023.
  • The results showed that the addition of evenamide improved symptoms of psychosis in patients with TRS.
  • Recruitment at treatment centers in Europe, Asia and Latin America is ongoing and results are expected in 2023.
  • ESG focus areas and objectives for 2023 have been defined and Newron’s Annual ESG reporting efforts commence with the Annual Report 2022 published today.

Newron Announces 2022 Financial Results and Provides Outlook For 2023

Retrieved on: 
Tuesday, March 14, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, PANSS, Orange Book, Sustainability, Annual report, Tablet, Peripheral nervous system, Psychosis, TRS, Intellectual property, Positive, ESG, XETRA, Social, EUR, Clinical Global Impression, Environment, Abbreviated New Drug Application, Levodopa-induced dyskinesia, PD, Annual, Sale, Social Security Government Pension Offset, Patient, Schizophrenia, UN, Food, Clozapine, Medication, Paragraph, Trial of the century, Safety, R, Phase, FDA, AGM, Sympathetic nervous system, Positive and Negative Syndrome Scale, Sustainable Development Goals, Sustainable development, Partnership, US Foods, Pharmaceutical industry, Nursing, Cryptocurrency, Newron Cup

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2022, and provided an outlook for 2023.

Key Points: 
  • Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2022, and provided an outlook for 2023.
  • The results showed that the addition of evenamide improved symptoms of psychosis in patients with TRS.
  • Recruitment at treatment centers in Europe, Asia and Latin America is ongoing and results are expected in 2023.
  • ESG focus areas and objectives for 2023 have been defined and Newron’s Annual ESG reporting efforts commence with the Annual Report 2022 published today.

Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™

Retrieved on: 
Wednesday, February 22, 2023
Tissue, Lysosome, GM1, Skin, Glycogen storage disease, MBBS, Patient, Half-life, Pain, Disease, Heart, Kaay Raav Tumhi, Partnership, ERT, Fabry disease, Abstract, CNS, Enzyme, Kidney, AAV, Serum, Fatigue, Transgene, Peripheral nervous system, Takeda Pharmaceutical Company, Protein engineering, OnDemand, DSM-IV codes, Poster, Enzyme replacement therapy, Pharmaceutical industry, Vaccine, Takeda, Fabry, Codexis

REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19 th Annual WORLDSymposium™ , taking place from February 22-26, 2023, in Orlando, Florida.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19 th Annual WORLDSymposium™ , taking place from February 22-26, 2023, in Orlando, Florida.
  • Takeda is combining these improved transgenes with its gene therapy capabilities to develop novel product candidates for the treatment of rare genetic disorders.
  • Takeda’s poster presentation, titled, “Preventing Fabry disease progression in a symptomatic mouse model with a recombinant adeno-associated virus (rAAV) based gene therapy,” highlights its rAAV-based gene therapy candidate for the potential treatment of Fabry disease.
  • Codexis is also presenting two abstracts highlighting its gene therapy program in GM1 Gangliosidosis (GM1) at WORLDSymposium™.

Forge Biologics Reports Positive FBX-101 Clinical Updates for Patients with Krabbe Disease at WORLDSymposium

Retrieved on: 
Thursday, February 23, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, Cerebrospinal fluid, Psychosine, Safety, Central nervous system, University, HSCT, Improvement, GALC, Risk, CSF, Krabbe disease, Hematopoietic stem cell transplantation, Standard of care, Intravenous therapy, CNS, PNS, Inflammation, Plasma, Infant, Human, AAV, Peripheral nervous system, Multimedia, Pharmaceutical industry, Patient, Forge

Forge has also dosed the first FBX-101 subject in the REKLAIM Phase 1b clinical trial at the University of Michigan Medical Center.

Key Points: 
  • Forge has also dosed the first FBX-101 subject in the REKLAIM Phase 1b clinical trial at the University of Michigan Medical Center.
  • View the full release here: https://www.businesswire.com/news/home/20230223005450/en/
    Patients with infantile Krabbe disease have mutations in the gene encoding the lysosomal enzyme galactocerebrosidase (GALC), which is essential for normal metabolism of myelin components.
  • This results in progressive motor disease and often early death of patients by two years of age.
  • Notably, some of the patients were identified by newborn screening, which enabled early disease intervention,” stated Dr. Escolar.